Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (193)	6/22/2000 12:40:00 PM
From: Jim Oravetz	of 370

Vion says Promycin studies halted after evaluation NEW HAVEN, Conn., June 22 (Reuters) - Vion Pharmaceuticals Inc. (NASDAQ: VION) said on Thursday that licensee Boehringer Ingelheim of Germany put further clinical studies of Viox's anti-cancer agent Promycin on hold because a Phase III trial was not meeting pre-determined criteria in an interin evaluation. In the trial, Promycin was combined with radiotherapy versus radiotherapy alone in patients with head and neck cancer. Boehringer maintains full managerial and financial responsibility for Promycin's development. snip... siliconinvestor.com Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next